Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acarbose derived trisaccharide is a synthetic or natural compound related to the structure of acarbose and its metabolites. It belongs to the class of aminocyclitol glycosides and has been reported in Streptomyces diastaticus. The compound is considered experimental and has not been approved for any clinical use. Its mechanism of action is presumed similar to that of acarbose—an inhibitor of alpha-glucosidase enzymes—which delays carbohydrate digestion in the intestine and reduces postprandial blood glucose levels. However, this specific derivative does not have documented clinical indications or approvals[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-O-(4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-beta-D-lyxo-hexopyranosyl)-alpha-D-erythro-hexopyranose.